---
title: "GemPharmatech Co., Ltd. (688046.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688046.SH.md"
symbol: "688046.SH"
name: "GemPharmatech Co., Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T14:04:48.260Z"
locales:
  - [en](https://longbridge.com/en/quote/688046.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688046.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688046.SH.md)
---

# GemPharmatech Co., Ltd. (688046.SH)

## Company Overview

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company has a strategic alliance with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.gempharmatech.com](https://www.gempharmatech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.34)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 5 / 25 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 18.56% |  |
| Net Profit YoY | 44.81% |  |
| P/B Ratio | 3.81 |  |
| Dividend Ratio | 0.66% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8683699892.76 |  |
| Revenue | 829816967.26 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.20% | B |
| Profit Margin | 19.23% | A |
| Gross Margin | 64.07% | A |
| Revenue YoY | 18.56% | B |
| Net Profit YoY | 44.81% | B |
| Total Assets YoY | 8.19% | B |
| Net Assets YoY | 5.41% | C |
| Cash Flow Margin | 156.27% | B |
| OCF YoY | 18.56% | B |
| Turnover | 0.30 | D |
| Gearing Ratio | 20.54% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - GemPharmatech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "18.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "44.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.66%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8683699892.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "829816967.26",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.20%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "19.23%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "64.07%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "18.56%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "44.81%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.19%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.41%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "156.27%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "18.56%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.54%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 53.00 | 9/25 | 63.81 | 57.43 | 51.32 |
| PB | 3.72 | 18/25 | 3.47 | 3.19 | 2.85 |
| PS (TTM) | 10.19 | 20/25 | 10.17 | 9.33 | 8.37 |
| Dividend Yield | 0.68% | 6/25 | 1.28% | 0.82% | 0.75% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.65 |
| Highest Target | 27.96 |
| Lowest Target | 27.96 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688046.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688046.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688046.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**